Vitamin D supplementation to persistent carriers of MRSA-a randomized and placebo-controlled clinical trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Methicillin-resistant Staphylococcus aureus (MRSA) is resistant to all beta-lactam antibiotics and can cause severe infections that are difficult to treat.

The primary endpoint was the decline in MRSA positivity during the study period.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

In total, n = 65 persistent MRSA carriers were randomized and n = 3 were lost to follow-up.

What Was Measured

The primary endpoint was the decline in MRSA positivity during the study period.

The subject headings attached to it are Carrier State, Dietary Supplements, Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections, Sweden and Vitamin D.

Author keywords: Clinical trial, Immunity and Methicillin-resistant S. aureus (MRSA).

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2018 (European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.